Catalyst Pharmaceuticals reports positive results

Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) reported positive results from the investigator-sponsored trial of Firdapse to treat myasthenia gravis patients with anit-MuSK antibodies. Shares of the biopharmaceutical climbed 38 cents to close at $1.55.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.